glp 1 cirrhosis Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive Exploring Glucagon-like Peptide-1 receptor agonist
Description
Type 2 diabetes is a risk factor for both AD and PD

Approved in 2022 for diabetes (brand Mounjaro), tirzepatide produced extraordinary results in weight loss up to ~22% in obese participants at the highest dose in a phase 3 trial ( [137] )
...amyloid plaques and tau tangles may be consequences rather than root causes of biological stress signals arising when neurons do not receive sufficient blood flow and are under-nourished

Weight-loss prescriptions for Wegovy or off-label use usually require a Letter of Medical Necessity stating that the treatment is medically necessary and not for cosmetic or general wellness purposes
)
Were giving your body time to adapt, and were identifying your therapeutic window where benefits are strong and side effects stay reasonable

They also pushed for early motions to dismiss by requesting objective testing for gastroparesis, which can complicate the plaintiffs burden of proof
